MSM

MSM Protein Technologies is a private U.S. biotechnology company focused on discovery and early development of fully human therapeutic antibodies against difficult integral membrane protein targets, especially G-protein-coupled receptors. The company positions itself as a specialist in antibody discovery for multi-spanning membrane proteins and has built a proprietary platform combining phage display, mammalian cell display, immunization methods, and native-conformation target expression. In addition to its internal preclinical pipeline, MSM has conducted collaborative drug discovery programs for external partners. Its stated disease focus spans oncology, autoimmune and inflammatory disorders, and respiratory disease. The company appears to remain active and is seeking licensing, co-development, and collaboration opportunities for its antibody portfolio and platform.